Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 20;17(2):521–531. doi: 10.1158/1535-7163.MCT-17-0575

Figure 2. Necitumumab binds with high affinity to sEGFR harboring the cetuximab resistance mutations S468R.

Figure 2

A and B, SPR analysis of sEGFR, sEGFR-S468R and sEGFRd3-S468R binding to immobilized cetuximab (A) and necitumumab (B) Fabs. Normalized equilibrium SPR response plotted as a function of protein concentration were fit to a simple one-site Langmuir binding equation. Data are representative of at least three independent measurements. Mean KD values with standard deviations are reported in Supplementary Table S2.